285 related articles for article (PubMed ID: 7718484)
1. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf.
Topol LZ; Marx M; Calothy G; Blair DG
Cell Growth Differ; 1995 Jan; 6(1):27-38. PubMed ID: 7718484
[TBL] [Abstract][Full Text] [Related]
2. Activation of the mitogen-activated protein kinase cascade in response to the temperature inducible expression of v-mos kinase.
Topol LZ; Blair DG
Cell Growth Differ; 1995 Sep; 6(9):1119-27. PubMed ID: 8519689
[TBL] [Abstract][Full Text] [Related]
3. SCH 51344 inhibits ras transformation by a novel mechanism.
Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of insulin on the activation of the Raf/Mos-dependent MAP kinase cascade in vitellogenic versus postvitellogenic Xenopus oocytes.
Chesnel F; Bonnec G; Tardivel A; Boujard D
Dev Biol; 1997 Aug; 188(1):122-33. PubMed ID: 9245517
[TBL] [Abstract][Full Text] [Related]
5. Evidence for involvement of the protein kinase C pathway in the activation of p37v-mos protein kinase.
al-Bagdadi F; Singh B; Arlinghaus RB
Oncogene; 1990 Aug; 5(8):1251-7. PubMed ID: 2168030
[TBL] [Abstract][Full Text] [Related]
6. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum.
Kolch W; Heidecker G; Troppmair J; Yanagihara K; Bassin RH; Rapp UR
Oncogene; 1993 Feb; 8(2):361-70. PubMed ID: 8426742
[TBL] [Abstract][Full Text] [Related]
7. Delay in serum stimulation of Erk activity caused by oncogenic transformation.
Greulich H; Reichman C; Hanafusa H
Oncogene; 1996 Apr; 12(8):1689-95. PubMed ID: 8622889
[TBL] [Abstract][Full Text] [Related]
8. Multiple pathways for activation of MAP kinases.
Mitra G; Weber M; Stacey D
Cell Mol Biol Res; 1993; 39(5):517-23. PubMed ID: 8173594
[TBL] [Abstract][Full Text] [Related]
9. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
10. A role for Ras in v-Crk transformation.
Greulich H; Hanafusa H
Cell Growth Differ; 1996 Nov; 7(11):1443-51. PubMed ID: 8930393
[TBL] [Abstract][Full Text] [Related]
11. A dominant suppressive mutation in a cellular gene restores the nontransformed phenotype to v-fms-transformed mink cells.
Kato J; Sherr CJ
Oncogene; 1991 May; 6(5):687-93. PubMed ID: 2052353
[TBL] [Abstract][Full Text] [Related]
12. v-raf confers CSF-1 independent growth to a macrophage cell line and leads to immediate early gene expression without MAP-kinase activation.
Büscher D; Dello Sbarba P; Hipskind RA; Rapp UR; Stanley ER; Baccarini M
Oncogene; 1993 Dec; 8(12):3323-32. PubMed ID: 8247534
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter.
Kukushkin AN; Abramova MV; Svetlikova SB; Darieva ZA; Pospelova TV; Pospelov VA
Oncogene; 2002 Jan; 21(5):719-30. PubMed ID: 11850800
[TBL] [Abstract][Full Text] [Related]
14. A single Glu(62)-to-Lys(62) mutation in the Mos residues of the R7Delta447Gag-tMos protein causes the mutant virus to induce brain lesions.
Yuen PH; Ryan EA; Devroe E; Wong PK
Oncogene; 2001 Feb; 20(6):692-703. PubMed ID: 11314003
[TBL] [Abstract][Full Text] [Related]
15. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor.
York RD; Yao H; Dillon T; Ellig CL; Eckert SP; McCleskey EW; Stork PJ
Nature; 1998 Apr; 392(6676):622-6. PubMed ID: 9560161
[TBL] [Abstract][Full Text] [Related]
16. Isolation of a new class of 'flat' revertants from ras-transformed NIH3T3 cells using cis-4-hydroxy-L-proline.
Yanagihara K; Ciardiello F; Talbot N; McGeady ML; Cooper H; Benade L; Salomon DS; Bassin RH
Oncogene; 1990 Aug; 5(8):1179-86. PubMed ID: 2202950
[TBL] [Abstract][Full Text] [Related]
17. Repression of mitogen-activated protein kinases ERK1/ERK2 activity by a protein tyrosine phosphatase in rat fibroblasts transformed by upstream oncoproteins.
Gopalbhai K; Meloche S
J Cell Physiol; 1998 Jan; 174(1):35-47. PubMed ID: 9397154
[TBL] [Abstract][Full Text] [Related]
18. Constitutively active mitogen-activated protein kinase kinase 1 (MAPKK1) and MAPKK2 mediate similar transcriptional and morphological responses.
Mansour SJ; Candia JM; Gloor KK; Ahn NG
Cell Growth Differ; 1996 Feb; 7(2):243-50. PubMed ID: 8822208
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of v-mos Ser 47 by the mitotic form of p34cdc2.
Bai WL; Singh B; Karshin WL; Shonk RA; Arlinghaus RB
Oncogene; 1991 Oct; 6(10):1715-23. PubMed ID: 1833715
[TBL] [Abstract][Full Text] [Related]
20. Mitogenesis by v-Src: fluctuations throughout G1 of classical immediate early AP-1 and mitogen-activated protein kinase responses that parallel the need for the oncoprotein.
Wyke AW; Frame MC; Gillespie DA; Chudleigh A; Wyke JA
Cell Growth Differ; 1995 Oct; 6(10):1225-34. PubMed ID: 8845299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
